Ahmad F. Thabet

Ahmad F. Thabet

Auto-generated profile, based on publicly available information

Ahmad F. Thabet

Department of Internal Medicine, Clinical Hematology Unit, Faculty of Medicine, Assiut University, Assiut, Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2017 in Journal of Renal Care
Verified
Journal Article
Closed access
PDF file
ATAhmad F. Thabet
Ahmad F. Thabet
SMSawsan M. Moeen
Sawsan M. Moeen
MLMohammed O. Labiqe
Mohammed O. Labiqe
MSMedhat A. Saleh
Medhat A. Saleh

20 February 2020 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
AZAsmaa M. Zahran
Asmaa M. Zahran
SMSawsan M. Moeen
Sawsan M. Moeen
ATAhmad F. Thabet
Ahmad F. Thabet
ARAmal Rayan
Amal Rayan
MAMona Hussein Abdel-Rahim
Mona Hussein Abdel-Rahim
Helal HettaHelal Hetta
Helal Hetta
This study aimed to analyze the frequency of peripheral Mo-myeloid-derived suppressor cells (Mo-MDSCs) in newly diagnosed CLL patients and to correlate their level with other prognostic factors such as frequency of CD38 cells and ZAP-70 cells and with the clinical response and survival outcomes in these patients. Fifty CLL patients and 20 age-matched healthy controls were included in this study. Flow cytometric detection of ZAP 70, CD38, and Mo-MDSCs was done. Mo-MDSC levels wer significantly higher in CLL patients (27.51 ± 1.70) than healthy controls (16.79 ± 0.66; p < .0001). Higher levels of Mo-MDSCs were detected in advanced Rai clinical staging than Stage I. Mo-MDSCs level was significantly correlated with the frequency of CD38 (r = 0.505; p < .0001) and ZAP-70 cells (r = 0.421; p < .0001). Higher levels of Mo-MDSCs predict poor survival in CLL patients with Mo-MDSCs levels 25% (n = 29; log - Rank test, p < .0001). In conclusion, Mo-MDSCs are correlated with tumor progression and a poor prognosis in CLL.

15 August 2013 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
ATAhmad F. Thabet
Ahmad F. Thabet
MFMostafa Faisal
Mostafa Faisal

8 April 2015 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
IMIsmail L. Mohamad
Ismail L. Mohamad
Khaled SaadKhaled Saad
Khaled Saad
AAAli Abdel-Azeem
Ali Abdel-Azeem
SMSherif A.A. Mohamed
Sherif A.A. Mohamed
HOHisham A.K. Othman
Hisham A.K. Othman
AEAmira A. El-Houfey
Amira A. El-Houfey
Background: Diabetes mellitus is a leading cause of morbidity and mortality among children across the world and is responsible for a growing proportion of global healthcare expenditure. However, limited data are available on lung dysfunction in children with diabetes. Aim: The aim of this study was to evaluate the pulmonary function changes in children with type 1 diabetes mellitus (T1DM). Methods: We studied 60 children with T1DM (mean age 10.5 ± 2.32 years; disease duration 2.45 ± 0.6 years, and 50 healthy control children (mean age 9.9 ± 2.5 years). Spirometry was performed for all individuals to measure forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow rate (PEFR). Glycemic control was assessed on the basis of glycated hemoglobin (HbA1c), with HbA1c values <8% considered to indicate good glycemic control, and HbA1c values ⩾8% to indicate poor control. Results: There was significant reduction in all spirometeric parameters in diabetic children in comparison with healthy control children. Children with poor glycemic control had significant impairment in lung functions compared with those with good glycemic control. Conclusions: T1DM in children leads to impairment of lung functions and this impairment increases with poor glycemic control.

11 October 2019 in Platelets
Verified
Journal Article
Closed access
ATAhmad F. Thabet
Ahmad F. Thabet
SMSawsan M. Moeen
Sawsan M. Moeen
Treatment of chronic primary immune thrombocytopenia (ITP) is challenging especially with limited resources and therapy-related complications. This prospective interventional study assessed the efficacy and safety of triple therapy(TT4); a combination treatment of oral dexamethasone 40 mg for days1-4, oral cyclosporine A 2–3 mg/kg daily for 28 consecutive days and intravenous rituximab 100 mg for days7,14,21 and 28 among 40 patients with ITP who failed previous 2 or more treatment options. Our aim was to maintain platelet count ≥ 30 X 109/L without any obvious bleeding at any point in the study. Platelet counts were assessed weekly for a month then monthly for 2 years to evaluate the long-term response. TT4 was well tolerated and induced a good response with a significant increase in the mean platelet count after the 1st, 2nd, 3rd, and 4thweek compared to the baseline. Patients with mean platelet count ≥ 30 X 109/L at the 6th month were 75% (30/40 patients). Treatment free survivals (TFS) at 12 and 24 months were 93.3% (28/30 patients) and 80% (24/30 patients) respectively. TT4 is an effective treatment option that maintained platelet count in the desired level and induced a higher sustained response, especially in an environment with limited resources.

9 March 2020 in Platelets
Verified
Journal Article
Closed access
GAGhada E. M. Abdallah
Ghada E. M. Abdallah
EEEsam A. S. Elbiih
Esam A. S. Elbiih
DSDouaa Sayed
Douaa Sayed
SMSawsan M. Moeen
Sawsan M. Moeen
SGShima Gafer
Shima Gafer
ATAhmad F. Thabet
Ahmad F. Thabet
The balance between therapy effectiveness and economic efficiency in chronic immune thrombocytopenia (ITP) becomes more confusing. This single-center open label randomized controlled trial evaluates the effectiveness and safety of hydroxychloroquine in chronic ITP patients against other affordable second-line treatments. It is registered under number (NCT03229746) at Clinical Trials.gov. 120 patients were recruited and randomly allocated to three arms of hydroxychloroquine, vincristine, and azathioprine equally. Platelet counts of more than 100 × 109/L were interpreted as complete response (CR), while response (R) was determined as platelet counts ranging from 30 × 109/L to less than 100 × 109/L with the doubling of the pretreatment platelet count. Overall response (OR) was defined to include both CR and R. Patients were monitored every 6 weeks for a total of 24 weeks. The population baseline characteristics regarding age, sex, duration of the disease, baseline platelets count, and presence of antinuclear antibodies ANA or antiplatelet antibodies were similar among tested groups. There was a significant difference in the overall response between hydroxychloroquine (80.6%) and azathioprine (55.9%) (p-value <0.05). This difference was not significant between hydroxychloroquine and vincristine group (63.2%) (p-value = 0.09). This study proves that hydroxychloroquine can contribute to the therapy of chronic ITP especially as an affordable and well-tolerated drug.